31/08/2017 07:11:46

NeuroSearch A/S – H1 report 2017

Related content
04 Jul - 
NeuroSearch and Saniona enter into agreement on transfe..
21 Mar - 
Report on Annual General Meeting of NeuroSearch A/S
07 Mar - 
Report pursuant to section 28a of the Danish Act on Sec..
Related debate
30 Aug - 
Mon Halvårsregnskabet fra Neurosearch bringer nyt? Noge..

Announcement

31 August 2017

 

Below please find the H1 report 2017. The full report is available in the enclosed PDF file.

The NeuroSearch Group posted an operating loss of DKK 2.3 million in H1 2017 (H1 2016: a loss of DKK 1.4 million).

A loss after tax of continuing operations of DKK 2.5 million was posted in H1 2017 (H1 2016: a loss of DKK 1.7 million).

A consolidated net loss of DKK 2.5 million was posted for H1 2017 (H1 2016: a net loss of DKK 0.5 million).

At 30 June 2017, cash and cash equivalents totalled DKK 66 million (30 June 2016: DKK 77 million). In H1 2017, NeuroSearch paid the DKK 5 million fine for market manipulation.

Update on the Company’s assets.

The Company has shareholdings in:

  • NsGene: 26.8% (NsGene entered into voluntary liquidation on 30 January 2017. NeuroSearch has recognised proceeds from the liquidation of DKK 4.5 million in its financial statements for 2016, which the Company expects to receive in Q3 2017).

  • Atonomics: 3.6%.

Licence agreements:

  • Potential milestone payments from Teva Pharmaceuticals (if Huntexil® is granted market approval, NeuroSearch will be entitled to receive milestone payments totalling up to DKK 55 million. In 2016, Teva Pharmaceutical Industries Ltd. announced positive data from a comprehensive Phase II study. NeuroSearch has no further insight into Teva’s future plans for developing Huntexil® and is therefore unable to assess the likelihood of payments to NeuroSearch being triggered or the timing of such payments. NeuroSearch has initiated a process to identify any possibilities of divesting the Company’s entitlement to potential milestone payments and potential royalties.).

  • Agreements with Saniona A/S. See more below in “Events after the balance sheet date”.

Except for the proceeds deriving from the liquidation of NS Gene, the value of the assets listed above is subject to substantial uncertainty as no established market exists for such assets.

 

In addition, NeuroSearch calculated the value as of 31 December 2016 of its unrecognised tax losses carried forward at approximately DKK 1,708 million, and deductible temporary differences at approximately DKK 84 million, or a total of approximately DKK 1,791 million. Under certain conditions, the unrecognised tax assets may be utilised in full or in part by a potential buyer of NeuroSearch.

Outlook for 2017

In 2017, NeuroSearch expects an operating loss in the range of DKK 2.3-3.3 million. The outlook does not include any income from the possible divestment of additional Company assets or potential income from the Company’s agreement with Teva.

Events after the balance sheet date

On 4 July 2017, NeuroSearch and Saniona entered into an agreement on transfer of the remaining rights in the preclinical and clinical assets which NeuroSearch divested to Saniona during the period 2012-2016. In full and final settlement of NeuroSearch’s remaining rights in the divested programs, NeuroSearch received from Saniona a one-time cash payment of DKK 5.5 million. Furthermore, Saniona assumed NeuroSearch’s royalty obligations to third parties regarding potential future net sales of products from the programs, including NeuroSearch’s royalty payment obligations to Boehringer Ingelheim (tesofensine) and to GlaxoSmithKline (NS2359).

Of the DKK 5.5 million received, NeuroSearch will, as per the original agreement, pay DKK 0.4 million in total to Boehringer Ingelheim and GlaxoSmithKline. The remaining DKK 5.1 million will add DKK 2.2 million to the Company's operating income, and the DKK 2.9 million will be recognised in discontinued operations.

After receipt of the DKK 5.5 million, the Company’s cash and cash equivalents totalled DKK 71 million. The payment obligation to Boehringer Ingelheim and to GlaxoSmithKline is expected to be fulfilled in H2 2017.

Allan Andersen

CEO

Contact person

Allan Andersen, CEO, mobile+45 4016 3864

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Alliance Trust PLC : Net Asset Value(s)

25/09/2017 13:10:52
ALLIANCE TRUST PLC                                    At the close of business on Friday 22 September 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 748.1p -       including income, 756.0p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding in..

Form 8.5 (EPT/RI) - Booker Group plc

25/09/2017 08:07:28
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Alliance Trust PLC : Transaction in Own Shares

25/09/2017 07:39:49
25 September 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 22 September 2017 the Company purchased for cancellation 54,330 ordinary shares of 2.5p each at a price of 704.6964p per share.  Therefore, the total number of voting rights in the Company is now 349,635,321.    The above figure (349,635,321) may be used by sh..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Gigya, the Market Leader in Customer Identity and Access Management, to be Acquired by SAP
2
iLOOKABOUT Launches New Mobile Appraiser Product at IAAO Conference
3
Aerojet Rocketdyne Supports ULA Launch of Classified Satellite for the U.S. Government
4
OCEANTEAM ASA - Dutch Jos van Dijk appointed Group Chief Financial Officer (CFO)
5
Thinfilm Launches NFC Scanner App for iPhones as Apple Extends NFC Functionality Beyond Payments with Release of iOS 11

Related stock quotes

NeuroSearch A/S 3.42 -0.3% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 September 2017 14:21:34
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170921.1 - EUROWEB3 - 2017-09-25 15:21:34 - 2017-09-25 14:21:34 - 1000 - Website: OKAY